گلمباتومومب وداتین (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "گلمباتومومب وداتین" in Persian language version.

refsWebsite

Global rank Persian rank

4^th place

5^th place

2^nd place

2^nd place

2web.archive.org

1^st place

1^st place

1currentcancer.com

low place

low place

1celldextherapeutics.com

low place

low place

1medicalnewstoday.com

3,011^th place

459^th place

low place

low place

bioworld.com

"Celldex TNBC trial failure dashes company's plans". BioWorld (به انگلیسی). Archived from the original on 18 June 2018. Retrieved 2018-04-17.

celldextherapeutics.com

"The EMERGE study" (PDF). Dec 2012.^{^{[پیوند مرده]}}

currentcancer.com

"Celldex Therapeutics Announces Initiation Of Randomized Phase 2b Clinical Trial Of CDX-011 In Advanced Breast Cancer". 22 Sep 2010.

doi.org

Qian X, Mills E, Torgov M, LaRochelle WJ, Jeffers M (2008). "Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate". Mol. Oncol. 2 (1): 81–93. doi:10.1016/j.molonc.2008.02.002. PMC 5527796. PMID 19383330.
Rose AA, Grosset AA, Dong Z, et al. (April 2010). "Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer". Clinical Cancer Research. 16 (7): 2147–2156. doi:10.1158/1078-0432.CCR-09-1611. PMID 20215530.
Tse KF, Jeffers M, Pollack VA, et al. (February 2006). "CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma". Clinical Cancer Research. 12 (4): 1373–82. doi:10.1158/1078-0432.CCR-05-2018. PMID 16489096.

medicalnewstoday.com

"CuraGen Announces Expansion Of CR011-vcMMAE Phase II Trial In Advanced Breast Cancer". 18 June 2009. Archived from the original on 20 June 2009. Retrieved 3 March 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Qian X, Mills E, Torgov M, LaRochelle WJ, Jeffers M (2008). "Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate". Mol. Oncol. 2 (1): 81–93. doi:10.1016/j.molonc.2008.02.002. PMC 5527796. PMID 19383330.
Rose AA, Grosset AA, Dong Z, et al. (April 2010). "Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer". Clinical Cancer Research. 16 (7): 2147–2156. doi:10.1158/1078-0432.CCR-09-1611. PMID 20215530.
Tse KF, Jeffers M, Pollack VA, et al. (February 2006). "CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma". Clinical Cancer Research. 12 (4): 1373–82. doi:10.1158/1078-0432.CCR-05-2018. PMID 16489096.

ncbi.nlm.nih.gov

Qian X, Mills E, Torgov M, LaRochelle WJ, Jeffers M (2008). "Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate". Mol. Oncol. 2 (1): 81–93. doi:10.1016/j.molonc.2008.02.002. PMC 5527796. PMID 19383330.

web.archive.org

"CuraGen Announces Expansion Of CR011-vcMMAE Phase II Trial In Advanced Breast Cancer". 18 June 2009. Archived from the original on 20 June 2009. Retrieved 3 March 2021.
"Celldex TNBC trial failure dashes company's plans". BioWorld (به انگلیسی). Archived from the original on 18 June 2018. Retrieved 2018-04-17.